Q2 2026 Holdings
Filed 2026-08-14 | 23 holdings | $697.5M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc(AMLX) | COM | 03237H101 | $83.0M | 4,624,101 | 11.9% |
| Alumis Inc(ALMS) | COM | 022307102 | $82.0M | 2,915,443 | 11.8% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $69.1M | 518,865 | 9.9% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $49.6M | 852,914 | 7.1% |
| Immix Biopharma Inc(IMMX) | COM | 45258H106 | $48.0M | 4,658,429 | 6.9% |
| Pharvaris N V(PHVS) | COM | N69605108 | $45.4M | 1,314,122 | 6.5% |
| Jazz Pharmaceuticals PLC(JAZZ) | SHS USD | G50871105 | $38.8M | 160,938 | 5.6% |
| Celcuity Inc(CELC) | COM | 15102K100 | $38.7M | 370,318 | 5.6% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $38.4M | 524,730 | 5.5% |
| Candel Therapeutics Inc(CADL) | COM | 137404109 | $34.0M | 3,303,686 | 4.9% |
| X4 Pharmaceuticals Inc(XFOR) | COM NEW | 98420X202 | $32.6M | 6,973,343 | 4.7% |
| Monopar Therapeutics Inc(MNPR) | COM NEW | 61023L207 | $28.9M | 311,976 | 4.1% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $23.5M | 1,057,493 | 3.4% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $19.6M | 1,052,043 | 2.8% |
| Zura BIO LTD(ZURA) | CLASS A ORD SHS | G9TY5A101 | $12.4M | 2,101,119 | 1.8% |
| Sagimet Biosciences Inc(SGMT) | COM SER A | 786700104 | $11.4M | 1,479,918 | 1.6% |
| Oculis Holding AG(OCS) | ORDINARY SHARES | H5870P102 | $9.5M | 684,880 | 1.4% |
| Inhibikase Therapeutics Inc(IKT) | COM NEW | 45719W205 | $7.9M | 3,869,056 | 1.1% |
| VIR Biotechnology Inc(VIR) | COM | 92764N102 | $7.9M | 770,643 | 1.1% |
| Invivyd Inc(IVVD) | COM | 00534A102 | $7.3M | 8,392,288 | 1.0% |
| Alto Neuroscience Inc(ANRO) | COM SHS | 02157Q109 | $4.8M | 182,829 | 0.7% |
| Satellos Bioscience Inc(MSLE) | COM | 80401L803 | $2.7M | 350,000 | 0.4% |
| Ovid Therapeutics Inc(OVID) | COM | 690469101 | $1.8M | 663,060 | 0.3% |